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Neal Flomenberg,1 Raymond L. Comenzo,2 Karin Badel,3 Gary Calandra3Rapid and durable recovery of hematopoietic function after hematopoietic stem cell transplantation (HSCT)
requires the infusion of a sufficient number of hematopoietic stem cells (HSC). Granulocyte colony-
stimulating factor (G-CSF), either alone or with chemotherapy, has been the traditional backbone of regi-
mens used to mobilize HSC. Plerixafor (previously known as AMD3100), a selective antagonist of
CXCR4, has recently been approved for autologous HSC mobilization in combination with G-CSF. The cur-
rent study assessed the safety and efficacy of plerixafor as a single agent when given subcutaneously and fol-
lowed by apheresis 6 hours later for the mobilization of HSC for transplantation in 9 patients with multiple
myeloma (MM). All patients mobilized enough cells for at least 1 transplant, and demonstrated prompt
recovery of hematopoietic function. Median time to engraftment was 10.5 days for neutrophils and 21
days for platelets. Significant adverse events were not observed. Recovery of peripheral blood cell counts
was durable in all surviving patients. Despite these successes, mobilization with plerixafor alone was modest.
However, in clinical circumstances where G-CSF or chemotherapy based-mobilization should not be used,
mobilization with plerixafor alone may be required and effective. Further research into single agent use
should focus on alternate route of administration as well as adjustment of the timing of the apheresis to
improve cell HSC yield (ClinicalTrials.gov registration number: NCT00396383).
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Successful hematopoietic stem cell transplantation
(HSCT) requires the infusion of a sufficient number
of hematopoietic progenitor cells and hematopoietic
stem cells (HSC) that are capable of homing to marrow
niches to rapidly and durably regenerate all hematopoi-
etic cell lineages. Granulocyte colony-stimulating fac-
tor (G-CSF), either alone or with chemotherapy, has
been the traditional backbone of regimens used to mo-
bilize HSC for autologous HSCT. The mechanisms of
mobilization are complex. In part, G-CSFmobilization
results from increased neutrophil production and
activation, which in turn, leads to the proteolyticThomas JeffersonUniversity, Philadelphia, Pennsylvania;
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6/j.bbmt.2009.12.538inactivation of adhesion molecules, and in part from
the activity of G-CSF on the sympathetic nervous
system in the osteoblast-rich stem cell niches. In these
niches, G-CSF causes a marked reduction in stromal-
derived factor (SDF)-1a (also called CXCL12) and
subsequent release of stem cells whose niche adherence
depends on the interaction of SDF-1 andCXCR4 [1-3].
Plerixafor (previously known as AMD3100) is a se-
lective antagonist of CXCR4 and reversibly blocks the
interaction between SDF-1a and CXCR4. A single
plerixafor injection results in a CD341 cell mobiliza-
tion on the same order of magnitude as that achieved
by a 5-day G-CSF mobilization regimen in healthy
volunteers [4,5] and has been demonstrated to
boost the number of HSC mobilized when added to
a G-CSF-based mobilization regimen [6-8].
Although mobilization and reinfusion of hemato-
poietic progenitor cells provides rapid short-term repo-
pulation in a transplant setting, durable hematopoietic
engraftment requires the mobilization of HSC with
long-term repopulating capacity. Compared to
G-CSF, plerixafor as a single agent mobilizes a more
primitive subset of CD341 cells, including long-term
repopulating HSC [9-12]. Devine and colleagues [13]
observed successful and durable engraftment in695
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by plerixafor alone, providing evidence that plerixafor
used as a single agent can mobilize cells with both
short-term and long-term repopulating potential.
Healthy individuals generally have higher circulat-
ing peripheral blood CD341 cell levels than patients
with hematologic diseases such as multiple myeloma
(MM) and non-Hodgkin lymphoma (NHL). Ques-
tions therefore remained as to whether plerixafor
used alone would be effective for peripheral stem cell
mobilization for autologous transplant in patients
with MM and NHL, leading to HSC collections that
would produce successful and durable engraftment fol-
lowing autologous transplantation. The current study,
the first clinical trial of HSC mobilization with single-
agent plerixafor in the autologous transplant setting,
was conducted to address these questions.METHODS
Study Design
This was a single-arm open-label study that was
conducted in 2 centers in the United States. A total
of 20 patients were planned in the protocol, and a stop-
ping rule was instituted to terminate the study if 5 of
the first 10 patients to be treated failed to mobilize at
least 2  106 CD341 cells/kg body weight over 4 con-
secutive apheresis days. This study was approved by
the local institutional review board, and all patients
provided written informed consent.Patient Population
Patients withMMwho were eligible for autologous
transplant were included if they were between 18 to 75
years of age, were in either first or second partial remis-
sion or complete remission, had received #2000 rad of
prior radiation therapy, had recovered from all acute
toxic effects of prior chemotherapy, demonstrated
a white blood count.3.0 109/L, an absolute neutro-
phil count.1.5109/L, aplatelet count.150109/L,
a serum creatinine #2.2 mg/dL, normal liver enzymes,
were negative for the human immunodeficiency virus,
and provided signed informed consent. Women of
child-bearing potential needed to be on an approved
form of contraception to be included.
Patients were excluded if they had received 2 or
more alkylating agents, received a total dose of $200
mg of prior melphalan (to limit prior melphalan expo-
sure to a low level, given the ability of this agent to
markedly decrease the ability to mobilize stem cells),
had any comorbid condition which, in the view of
the investigator, rendered the patient at high risk
from treatment complications, failed previous collec-
tions or collection attempts, had residual acutemedical
conditions resulting from prior chemotherapy, or hadbrain metastases, carcinomatous meningitis, acute
infection, fever, or hypercalcemia. Female patients
testing positively to a pregnancy test or lactating
females were excluded. Patients whose actual body
weight exceeded 175% of their ideal body weight,
those with a history of ventricular arrhythmias, and
those receiving thalidomide within 10 days prior to re-
ceiving the first dose of plerixafor were also excluded.Study Treatment and Transplantation
Plerixafor (0.24 mg/kg) was administered by sub-
cutaneous injection into the abdominal area 6 hours
prior to apheresis. Plerixafor was administered daily
for up to 4 consecutive days. Three blood volumes
were processed during each apheresis.
Prior to transplant, patients underwent ablative
chemotherapy and were subsequently transplanted
with HSC mobilized by plerixafor. Tandem trans-
plants were allowed under the protocol. Patients were
transplanted and monitored according to standard
practice at each center for 30 days after transplant
and then at 3, 6, and 12 months after transplant.Efficacy and Safety Assessments
The efficacy variables evaluated were the total
apheresis yield (CD341 cells/kg), the number of days
from transplant to neutrophil and platelet engraft-
ment, and graft durability, defined as the maintenance
of normal blood counts at 3, 6, and 12 months after
transplant. Neutrophil engraftment was defined as
a neutrophil count 0.5  109/L for 3 consecutive
days or 1  109/L for 1 day. Platelet engraftment
was defined as a platelet count of 20  109/L for
7 days without transfusion. CD341 cell numbers
were determined both by the local laboratory and
a central laboratory. Results from the local laboratory
were used to monitor apheresis and to determine the
number of cells for transplant. Central laboratory
results were used for analyses of efficacy data.
Safety was analyzed for all patients who received at
least 1 dose of plerixafor by monitoring adverse events
(AEs), serious adverse events (SAEs), concomitant
medications, physical examinations, vital signs, and
clinical laboratory tests. AEs occurring up to 30 days
after the final apheresis and SAEs occurring up to 6
months after transplant were collected.Statistical Methods
Categoric data were summarized in frequency
tables by the number and percent of patients falling
into each category. Continuous data were summarized
using descriptive statistics including the number of
observations, mean, standard deviation, median, and
minimum and maximum values.
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Patient Population
In this study, 9 patients received plerixafor and un-
derwent apheresis. Although all patients did receive
transplants with plerixafor-mobilized CD341 cells,
the study was terminated early because the investiga-
tors felt that the number of cells mobilized with pler-
ixafor alone did not warrant continuing enrollment.
Although the patients mobilized sufficient cells to
reach the proposed target of 2  106 CD341 cells/
kg, the investigators concluded that there would be
little enthusiasm in the community to pursue this
approach if sufficient cells for 2 transplants could not
be consistently mobilized.
Follow-up information at the 3-month visit was
available for 9 patients. Two patients died because of
disease progression before the 6-month follow-up visit
and 1 was lost to follow-up before the 6-month visit.
Six patients completed the 12-month follow-up visit.
Patient demographic and baseline characteristics are
summarized in Table 1. The patients were predomi-
nantly Caucasian (78%), female (67%), and ranged
in age from 49 to 74 years with a median weight of
80.3 kg (range: 51.3-97.5 kg). The patients were all
Durie Salmon Stage II (33%) or Stage III (67%) at
study entry, and were a mean of 10 months from diag-
nosis. Two patients had experienced disease progres-
sion or relapse #6 months before enrolment. All
patients had received prior chemotherapy. Most pa-
tients had received a single prior regimen for an aver-
age of about 6 months prior to stem cell collection.
Two patients had received prior lenalidomide therapy.Efficacy
Nine patients underwent plerixafor treatment and
apheresis. Results for the total number of CD341 cells
collected, the number of days to neutrophil and plate-
let engraftment, and graft durability are summarized in
Table 2. All patients, according to central laboratory
data, achieved total apheresis yields of CD341 cells
of$2 106 CD341 cells/kg. The number of cells col-
lected per patient ranged from 2.27  106 CD341
cells/kg to 6.64  106 CD341 cells/kg. Four patients
collected a total apheresis yield of $4  106 CD341
cells/kg according to central laboratory data.
All 9 patients received a transplant. The median
time to neutrophil engraftment was 10.5 days (range:
10-11 days, n5 9) and the median time to platelet en-
graftment was 21 days (range: 15-33 days, n5 8). One
patient could not be assessed for date of platelet en-
graftment because the necessary samples over a week’s
time after last platelet transfusion were not collected.
However, a platelet count of 52  109/L, obtained
on day 105, demonstrated that the patient had success-
ful platelet engraftment though the specific date ofengraftment could not be ascertained. Two patients
died because of disease progression before the 6-
month follow-up visit with durable grafts at the time
of their last clinical evaluations. One patient under-
went a planned second transplant 3 months after the
plerixafor mobilized transplant using G-CSF mobi-
lized stem cells collected after Plerixafor mobilization,
but prior to the first transplant. This patient had dura-
ble engraftment until the time of conditioning for the
second transplant, but could not be evaluated for dura-
ble engraftment from the plerixafor mobilized stem
cells thereafter. The remaining 6 patients were all
found to have durable engraftment at their 12-month
follow-up visits.
Safety
All 9 patients experienced at least 1 AE during ei-
ther collection or transplant. AEs occurring during
the mobilization/ treatment phase were mild to mod-
erate in severity and none were considered definitely
related to treatment. Five patients had AEs that were
considered unrelated (ie, not related or probably not
related) to plerixafor and 4 patients had AEs that
were considered related (ie, possibly or probably re-
lated) to plerixafor. The most common drug-related
AEwere injection site reactions, gastrointestinal disor-
ders, oral paraesthesias, and headache. There were no
drug-related SAEs in the study.
No patients died during the treatment/apheresis
phase. Two patients died of disease progression
between 3 and 6 months after transplant.DISCUSSION
This study provided evidence that plerixafor may
be used alone without G-CSF to mobilize HSC for au-
tologous transplantation in MM patients. Plerixafor
(0.24 mg/kg) was administered subcutaneously and
apheresis was initiated 6 hours after injection. Patients
required 3 to 4 days of apheresis to collect at least 2 
106 CD341 cells/kg; therefore, the total CD341 cell
yields could be deemed modest. Only 3 patients col-
lected sufficient CD341 cells for tandem transplant.
Based on these observations, we decided that the study
should be terminated after 9 patients were enrolled as
mobilization with Plerixafor alone did not seem to
consistently mobilize sufficient cells for tandem trans-
plantation, a common current practice in the treat-
ment of MM. Comparative mobilization with
G-CSF alone was not incorporated into this trial. None-
theless, several conclusions can be drawn that can help
guide future research initiatives and clinical practice.
The use of plerixafor alone was well tolerated, as
has been the case in other studies of this agent alone
or when combined with G-CSF. Used by itself, plerix-
afor can mobilize sufficient CD341 cells for
Table 1. Patient Demographics and Baseline Characteristics
Total number of patients 9
Age in years (median: range) 63: 49-74
Sex (male: female) 3: 6
Ethnic group
White 7 (77.8%)
African-American 2 (22.2%)
Weight (kg) 77.6 ± 13.3
Stage of disease (Durie Salmon)
I 0 (0%)
II 3 (33.3%)
III 6 (66.7%)
Months since diagnosis 10.2 ± 7.2
Months sine most recent progression/
relapse
3.5 ± 3.5
Prior chemotherapy 9 (100%)
Number of regimens (mean, range) 1.2, 1-2
Number of months of treatment
(mean, range)
5.9, 3-9
Number receiving prior Lenalidomide 2
Prior radiation therapy 1 (11.1%)
Site irradiated T spine 32-50 Gray
Data presented as mean 6 standard deviation except as indicated.
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modest CD341 cell doses used for transplant, prompt
and typical neutrophil (median 10.5 days) and platelet
(median 20 days) recoveries were seen, comparable to
recovery using CD341 cells mobilized with other
agents. Moreover, blood cell count recovery was dura-
ble. This suggests that cells mobilized with plerixafor
alone are operationally functional in all respects. If
G-CSF cannot be utilized, mobilization with plerixa-
for alone is thus an alternative to a bone marrow
harvest. Although cost, patient comorbidities, and
physician preference will dictate how each clinical se-
lection is handled, plerixafor mobilization is associated
with the more rapid pattern of engraftment commonly
seen with use of mobilized, peripheral blood stem
cells rather than the slower pattern of engraftment
commonly seen using autologous bone marrow.
Our observations are in agreement with those
made by Devine and colleagues [13] in allogeneic
transplantation, where donors received plerixaforTable 2. Summary of Outcomes: CD34+ Cell Yield, Engraftment, a
CD34+ Cells Collected
(106 Cells/kg) by Central Lab
Patient Number Patient Age Day 1 Day 2 Day 3 Day 4
01-101 49 0.65 0.63 0.80 0.66
01-102 63 1.81 0.90 1.69 2.24
01-103 57 2.66 1.16 0.43 0.39
01-104 55 1.40 1.02 1.32 1.06
03-105 63 1.37 1.01 0.69 0.75
03-106 74 1.85 1.59 1.55 —
03-107 70 0.50 0.59 0.67 0.51
03-108 58 0.47 0.60 0.68 0.92
03-109 69 0.88 0.76 0.95 1.07
PMN indicates polymorphonuclear neutrophils; PLT, platelets.
*This patient could not be evaluated after 3 months because of receipt of a pla
CSF) mobilized stem cells collected after mobilization with Plerixafor, but prio
†This patient could not be assessed for time to platelet engraftment because t
day 105, but it is not possible to determine exactly when.0.24mg/kg subcutaneously (s.c.) with apheresis 6 hours
later. They reported that plerixafor alone could mobi-
lize hematopoietic stem cells from healthy donors and
that transplantation with plerixafor mobilized cells
produced prompt and durable engraftment. Interest-
ingly, most of the patients in that trial received\4 
106 CD341 cells/kg, similar to the cell doses in our
study.
Based on the data from these 9 consecutive patients,
we felt that it was unnecessary to continue enrollment
further. Although the adequate engraftment potential
of the mobilized cells was clearly demonstrated, the
cell yields were lower than anticipated and despite the
absence of a formal control group, were lower than
what the investigators inferred would have been ob-
tained with G-CSF alone. These 9 patients were not
heavily pretreated and only 2 had received prior lenali-
domide, an agent associatedwith difficulty inHSCmo-
bilization. Given this experience in MM patients,
further study in NHL patients who are typically more
heavily pretreated and more difficult to mobilize may
require modifications to the current study design. In
the current trial, the 6-hour interval between plerixafor
and HSC collection was selected, based on mobiliza-
tion in normal volunteers, to allow both drug adminis-
tration and apheresis to occur on the same day without
being overly inconvenient for either the patients or the
apheresis and cryopreservation laboratory staff.
Further research into single agent use should focus
on alternate route of administration and/or adjustment
of the timing of the apheresis to improve cell yields. In
the current study, more than half the patients had their
peak CD34 collections on days 3 or 4 and collected
more than half their CD34 cells on these 2 days.
Thus, in this trial, cell yield on days 1 and 2 did not ap-
pear to consistently predict the size or adequacy of the
final stem cell product. In prior studies, peak mobiliza-
tionwithPlerixafor occurredmore consistently on days
1-2 of HSC collection [6-8]. The difference may be
explained by the prior effects of G-CSF on the marrownd Graft Durability
Days to Engraftment
Total PMN PLT 12-Month Graft Durability
2.74 11 33 Durable
6.64 10 21 Durable
4.64 11 26 Dead at 6 months
4.80 10 19 Not evaluable*
3.82 11 21 Durable
4.99 10 23 Durable
2.27 11 NA† Dead at 6 months
2.67 10 15 Durable
3.66 11 17 Durable
nned second transplant using granulocyte colony stimulating factor (G-
r to the first transplant.
he necessary samples were not collected. Platelet recovery occurred by
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number, location, and adhesion of HSCs may have
already occurred because of theG-CSF prior to Plerix-
afor administration [1-3].
Phase II and phase III studies both demonstrate
that the efficacy of the combination of G-CSF with
plerixafor is superior to G-CSF alone in both MM
and NHL patients [6-8]. Plerixafor is now approved
in combination with G-CSF in the United States for
mobilization of peripheral stem cells for autologous
transplantation in MM and NHL patients. Nonethe-
less, plerixafor as a single agent may have a role in au-
tologous HSCT. Our report supports further study of
plerixafor as a single agent for HSC mobilization in
cases where high-dose G-CSF may cause excessive
toxicity, such as in patients with POEMS or with sys-
temic AL amyloidosis who are candidates for autolo-
gous HSCT and require HSC mobilization [14,15].
It should be noted that, to date, CD341 cell dosing
guidelines used in clinical trials are those obtained with
G-CSF or chemotherapy plus G-CSF mobilization.
The addition (or substitution) of plerixafor does not al-
ter the frequencies of CD341 cells expressing primi-
tive phenotypic makers, such as CD38 or CD133.,
but it may shift mobilization toward a more function-
ally primitive CD341 population with a higher
frequency of NOD/SCID spleen repopulating cells
[9-11]. Consequently, we do not know whether the
cell doses required when plerixafor is part of the mobi-
lization regimen are the same as those required with
other approaches to mobilization. It is conceivable
that fewer plerixafor-mobilized CD341 cells/kg may
be required for durable engraftment and long-term he-
matopoietic recovery. Plerixafor dosing has been safely
escalated in the treatment of HIV to doses far higher
than those used so far for mobilization [16], so further
dose escalation may be possible. It has also been sug-
gested that the number of CD341 cells mobilized by
plerixafor may be higher when the agent is adminis-
tered intravenously (i.v.) rather than s.c. [17]. There-
fore, future studies, investigating higher doses of
plerixafor administered i.v. for HSC mobilization,
are warranted as well.
At present, in most circumstances, plerixafor and
G-CSF should be used together for maximal mobiliza-
tion of patients with MM, NHL, and HD [6-8,18].
However, based onour results, if there are unusual clin-
ical circumstances where G-CSF or chemotherapy
based-mobilization should not be used, mobilization
with plerixafor alone may be effective for autologous
HSC collection and transplantation.ACKNOWLEDGMENTS
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